Cancer Communications
indexed by SCI
BMC

doi: 10.5732/cjc.011.10290
Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells
Jing-Xuan Pan, Ke Ding, Cheng-Yan Wang
Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510089, P. R. China
[Abstract] Niclosamide, an oral antihelminthic drug, has been used to treat tapeworm infection for about 50 years. Niclosamide is also used as a molluscicide for water treatment in schistosomiasis control programs. Recently, several groups have independently discovered that niclosamide is also active against cancer cells, but its precise mechanism of antitumor action is not fully understood. Evidence supports that niclosamide targets multiple signaling pathways (NF-&kgr;B, Wnt/&bgr;-catenin, Notch, ROS, mTORC1, and Stat3), most of which are closely involved with cancer stem cells. The exciting advances in elucidating the antitumor activity and the molecular targets of this drug will be discussed. A method for synthesizing a phosphate pro-drug of niclosamide is provided. Given its potential antitumor activity, clinical trials for niclosamide and its derivatives are warranted for cancer treatment.
Chinese Journal of Cancer 2012, Volume: 31, Issue 4, Page: 178-184
[ PDF Full-text ]
[ Html full-text ](PubMed Central)

[ PubMed ]

[Google Scholar]


Cite this article

Jing-Xuan Pan, Ke Ding, Cheng-Yan Wang. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer. 2012, 31(4):178-184. doi:10.5732/cjc.011.10290


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China